Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$349.58
+1.2%
$341.35
$267.83
$391.29
$186.52B0.422.28 million shs3.45 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$129.16
0.0%
$134.38
$104.46
$157.29
$160.39B0.316.75 million shs13.67 million shs
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$168.44
-1.7%
$169.95
$123.61
$179.64
$7.89B0.721.44 million shs1.48 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$232.81
+2.0%
$231.98
$149.04
$251.71
$549.25B0.267.30 million shs8.02 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,133.15
+0.7%
$974.59
$623.78
$1,166.29
$1.06T0.532.99 million shs4.12 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$635.45
+1.1%
$706.93
$485.00
$821.11
$66.47B0.251.16 million shs975,695 shs
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$400.61
+1.0%
$348.12
$234.60
$404.15
$360.05B0.646.67 million shs10.89 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$153.01
+0.6%
$146.90
$127.96
$160.59
$40.11B0.5812.67 million shs20.71 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+2.18%+2.71%+4.86%-6.48%+20.41%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.15%-5.17%-3.22%-10.34%+18.49%
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
+2.35%-0.47%+0.64%+2.31%+37.01%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+2.11%-1.17%+1.21%-5.09%+48.85%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+4.04%-0.15%+13.75%+13.57%+46.72%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+1.58%+1.16%-10.49%-17.25%+29.65%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
+5.07%+3.92%+9.19%+38.48%+32.25%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
+3.07%+0.80%+4.67%-0.41%+14.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$349.58
+1.2%
$341.35
$267.83
$391.29
$186.52B0.422.28 million shs3.45 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$129.16
0.0%
$134.38
$104.46
$157.29
$160.39B0.316.75 million shs13.67 million shs
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$168.44
-1.7%
$169.95
$123.61
$179.64
$7.89B0.721.44 million shs1.48 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$232.81
+2.0%
$231.98
$149.04
$251.71
$549.25B0.267.30 million shs8.02 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,133.15
+0.7%
$974.59
$623.78
$1,166.29
$1.06T0.532.99 million shs4.12 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$635.45
+1.1%
$706.93
$485.00
$821.11
$66.47B0.251.16 million shs975,695 shs
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$400.61
+1.0%
$348.12
$234.60
$404.15
$360.05B0.646.67 million shs10.89 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$153.01
+0.6%
$146.90
$127.96
$160.59
$40.11B0.5812.67 million shs20.71 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+2.18%+2.71%+4.86%-6.48%+20.41%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.15%-5.17%-3.22%-10.34%+18.49%
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
+2.35%-0.47%+0.64%+2.31%+37.01%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+2.11%-1.17%+1.21%-5.09%+48.85%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+4.04%-0.15%+13.75%+13.57%+46.72%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+1.58%+1.16%-10.49%-17.25%+29.65%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
+5.07%+3.92%+9.19%+38.48%+32.25%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
+3.07%+0.80%+4.67%-0.41%+14.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.48
Hold$353.811.21% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.90
Moderate Buy$156.9321.50% Upside
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
2.73
Moderate Buy$168.44N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.74
Moderate Buy$253.048.69% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,227.008.28% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.70
Moderate Buy$792.6524.74% Upside
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
2.78
Moderate Buy$404.420.95% Upside
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
2.76
Moderate Buy$153.01N/A

Current Analyst Ratings Breakdown

Latest XLV, IBB, JNJ, GILD, LLY, REGN, UNH, and AMGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2026
Amgen Inc. stock logo
AMGN
Amgen
Set Price Target$389.00
6/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight
6/4/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
Boost Price TargetOverweight$395.00 ➝ $453.00
6/4/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
UpgradeNeutralBuy$420.00 ➝ $450.00
6/1/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Reiterated RatingOverweight$122.00
6/1/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
UpgradeHoldModerate Buy
6/1/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
Boost Price TargetBuy$395.00 ➝ $440.00
5/28/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
DowngradeBuy (B)Buy (B-)
5/27/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
Set Price Target$492.00
5/27/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
Boost Price TargetOutperform$444.00 ➝ $492.00
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,133.00 ➝ $1,251.00
(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$36.75B5.13$34.21 per share10.22$16.08 per share21.74
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B5.45$10.47 per share12.34$18.23 per share7.09
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B5.95$14.41 per share16.16$33.85 per share6.88
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B16.37$25.32 per share44.76$28.07 per share40.37
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B4.68$42.42 per share14.98$295.66 per share2.15
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$447.57B0.81$21.48 per share18.65$110.49 per share3.63
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$14.3724.3314.753.4720.96%137.41%13.28%8/4/2026 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B$7.3417.6013.55N/A30.99%48.19%18.28%8/6/2026 (Estimated)
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6526.9118.482.2421.83%32.60%13.29%7/15/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1540.2525.431.2334.98%105.77%23.76%8/5/2026 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$41.0415.4815.231.3829.65%13.16%10.17%7/30/2026 (Estimated)
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$12.06B$13.2430.2619.261.712.68%14.65%4.77%8/4/2026 (Estimated)
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/A21.15N/AN/AN/AN/AN/AN/A

Latest XLV, IBB, JNJ, GILD, LLY, REGN, UNH, and AMGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.91$2.03+$0.12$1.61$6.91 billion$6.96 billion
4/30/2026Q1 2026
Amgen Inc. stock logo
AMGN
Amgen
$4.77$5.15+$0.38$3.34$8.58 billion$8.62 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/29/2026Q1 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.91$9.47+$0.56$6.75$3.48 billion$3.61 billion
4/21/2026Q1 2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$6.76$7.23+$0.47$6.90$109.84 billion$111.65 billion
4/14/2026Q1 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.88%+8.27%70.15%14 Years
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.282.54%+3.04%44.69%10 Years
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.390.23%N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.362.30%+5.25%61.97%64 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.61%+15.18%24.58%11 Years
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.59%N/A9.16%N/A
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$8.842.21%+12.57%66.77%15 Years
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$2.501.63%N/AN/AN/A

Latest XLV, IBB, JNJ, GILD, LLY, REGN, UNH, and AMGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.822.45%6/15/20266/15/20266/29/2026
6/3/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
quarterly$2.322.45%6/15/20266/15/20266/23/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
4/14/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.33%5/26/20265/26/20266/9/2026
4/29/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.58%5/20/20265/20/20266/4/2026
3/16/2026
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
Quarterly$0.12180.29%3/17/20263/17/20263/20/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
5.65
1.26
1.01
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.89
1.97
1.77
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.46
1.03
0.77
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.57
2.96
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.69
0.80
0.80
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500539.71 million535.12 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A46.05 millionN/AOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410105.72 million98.35 millionOptionable
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
390,000908.14 million905.60 millionOptionable
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A262.11 millionN/ANot Optionable

Recent News About These Companies

State Street Health Care Select Sector SPDR ETF
State Street Health Care Select Sector SPDR ETF (XLV)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amgen stock logo

Amgen NASDAQ:AMGN

$349.58 +3.98 (+1.15%)
Closing price 04:00 PM Eastern
Extended Trading
$348.30 -1.28 (-0.37%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$129.16 -0.02 (-0.02%)
Closing price 04:00 PM Eastern
Extended Trading
$130.10 +0.94 (+0.72%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

iShares Biotechnology ETF stock logo

iShares Biotechnology ETF NASDAQ:IBB

$168.44 -2.99 (-1.74%)
As of 04:00 PM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$232.81 +4.64 (+2.03%)
Closing price 03:59 PM Eastern
Extended Trading
$232.28 -0.53 (-0.23%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,133.14 +7.88 (+0.70%)
Closing price 03:59 PM Eastern
Extended Trading
$1,125.00 -8.14 (-0.72%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$635.45 +6.72 (+1.07%)
Closing price 04:00 PM Eastern
Extended Trading
$633.48 -1.97 (-0.31%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

UnitedHealth Group stock logo

UnitedHealth Group NYSE:UNH

$400.61 +4.14 (+1.04%)
Closing price 03:59 PM Eastern
Extended Trading
$396.80 -3.81 (-0.95%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

Health Care Select Sector SPDR Fund stock logo

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$153.01 +0.93 (+0.61%)
Closing price 04:10 PM Eastern
Extended Trading
$153.62 +0.62 (+0.40%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.